

Alan S Coates

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10503739/publications.pdf>

Version: 2024-02-01

121
papers

23,401
citations

16411

64
h-index

19136

118
g-index

122
all docs

122
docs citations

122
times ranked

16497
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013, 24, 2206-2223.	0.6	2,805
2	A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 1081-1092.	13.9	1,694
3	A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 2747-2757.	13.9	1,465
4	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	0.6	1,449
5	Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2013, 14, 297-305.	5.1	998
6	Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. <i>Journal of Clinical Oncology</i> , 2007, 25, 486-492.	0.8	835
7	Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 3817-3827.	0.8	668
8	Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 3357-3365.	0.8	661
9	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 107-118.	13.9	621
10	Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 436-446.	13.9	588
11	Experience with 998 cutaneous melanomas of the head and neck over 30 years. <i>American Journal of Surgery</i> , 1991, 162, 310-314.	0.9	471
12	Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 766-776.	13.9	448
13	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 122-137.	13.9	448
14	Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98. <i>Journal of Clinical Oncology</i> , 2007, 25, 3846-3852.	0.8	407
15	Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. <i>Journal of Clinical Oncology</i> , 2016, 34, 927-935.	0.8	390
16	Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 3006-3014.	0.8	368
17	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. <i>Lancet Oncology</i> , The, 2011, 12, 1101-1108.	5.1	356
18	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1385-1393.	5.1	342

#	ARTICLE	IF	CITATIONS
19	Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93. <i>Journal of Clinical Oncology</i> , 2006, 24, 337-344.	0.8	328
20	CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 441-451.	3.0	316
21	Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole. <i>Journal of Clinical Oncology</i> , 2008, 26, 5569-5575.	0.8	299
22	Desmoplastic and desmoplastic neurotropic melanoma. <i>Cancer</i> , 1998, 83, 1128-1135.	2.0	295
23	Burdens and Benefits of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil and Tamoxifen for Elderly Patients With Breast Cancer: The International Breast Cancer Study Group Trial VII. <i>Journal of Clinical Oncology</i> , 2000, 18, 1412-1422.	0.8	279
24	Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1833-1846.	3.0	261
25	Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node-Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX. <i>Journal of Clinical Oncology</i> , 2013, 31, 3083-3090.	0.8	259
26	Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93. <i>Journal of Clinical Oncology</i> , 2006, 24, 1332-1341.	0.8	215
27	Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 207-212.	3.0	215
28	Effect of Pregnancy on Overall Survival After the Diagnosis of Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 1671-1675.	0.8	198
29	Early Start of Adjuvant Chemotherapy May Improve Treatment Outcome for Premenopausal Breast Cancer Patients With Tumors not Expressing Estrogen Receptors. <i>Journal of Clinical Oncology</i> , 2000, 18, 584-584.	0.8	181
30	Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. <i>Journal of Clinical Oncology</i> , 2016, 34, 2452-2459.	0.8	178
31	Missing quality of life data in cancer clinical trials: serious problems and challenges. , 1998, 17, 517-532.		176
32	Ki-67 expression in breast carcinoma. <i>Cancer</i> , 2003, 97, 1321-1331.	2.0	171
33	Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. <i>Lancet Oncology</i> , The, 2014, 15, 156-163.	5.1	171
34	Quality-of-Life Scores Predict Outcome in Metastatic but Not Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 3768-3774.	0.8	156
35	Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1571-1581.	3.0	150
36	Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 2221-2231.	0.8	148

#	ARTICLE	IF	CITATIONS
37	Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. <i>Lancet Oncology</i> , The, 2008, 9, 23-28.	5.1	145
38	Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. <i>Lancet Oncology</i> , The, 2015, 16, 848-858.	5.1	145
39	Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2772-2779.	0.8	141
40	Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. <i>Lancet</i> , The, 2001, 358, 277-286.	6.3	137
41	Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1117-1124.	0.8	134
42	Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 1972-1979.	0.8	133
43	Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4498-4504.	0.8	131
44	Psychosocial Predictors of Survival in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 2256-2256.	0.8	126
45	Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 5715-5722.	0.8	125
46	Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2966-2973.	0.8	121
47	Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. <i>Lancet</i> , The, 2005, 366, 1108-1110.	6.3	118
48	Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 709-717.	0.8	110
49	Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3967-3975.	0.8	108
50	Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1073-1079.	0.8	102
51	Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3113-3122.	0.8	101
52	Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1601-1610.	0.8	100
53	Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors—International Breast Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 1404-1410.	0.8	97
54	Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. <i>Journal of Clinical Oncology</i> , 2020, 38, 1293-1303.	0.8	93

#	ARTICLE	IF	CITATIONS
55	Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1179-1188.	0.8	91
56	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	5.1	91
57	Radical, modified, and selective neck dissection for cutaneous malignant melanoma. <i>Head and Neck</i> , 1995, 17, 232-241.	0.9	90
58	Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. <i>Annals of Oncology</i> , 2004, 15, 1749-1759.	0.6	90
59	Influence of Endocrine-Related Factors on Response to Perioperative Chemotherapy for Patients With Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 4141-4149.	0.8	81
60	Site of Primary Tumor Has a Prognostic Role in Operable Breast Cancer: The International Breast Cancer Study Group Experience. <i>Journal of Clinical Oncology</i> , 2005, 23, 1390-1400.	0.8	74
61	Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. <i>Breast</i> , 2013, 22, 1094-1100.	0.9	73
62	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 105-114.	0.8	72
63	Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. <i>Breast</i> , 2010, 19, 388-395.	0.9	69
64	Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 1955-1957.	0.8	67
65	Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Study Group Trial 15-95. <i>Journal of Clinical Oncology</i> , 2006, 24, 370-378.	0.8	67
66	The Role of the Number of Uninvolved Lymph Nodes in Predicting Locoregional Recurrence in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2019-2026.	0.8	67
67	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. <i>Journal of Clinical Oncology</i> , 2016, 34, 3400-3408.	0.8	65
68	Adjuvant Chemotherapy Followed By Goserelin Compared With Either Modality Alone: The Impact on Amenorrhea, Hot Flashes, and Quality of Life in Premenopausal Patients-The International Breast Cancer Study Group Trial VIII. <i>Journal of Clinical Oncology</i> , 2007, 25, 263-270.	0.8	61
69	Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1260-1263.	0.8	60
70	Adjuvant Endocrine Therapy Compared With No Systemic Therapy for Elderly Women With Early Breast Cancer: 21-Year Results of International Breast Cancer Study Group Trial IV. <i>Journal of Clinical Oncology</i> , 2003, 21, 4517-4523.	0.8	59
71	Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 221-226.	1.1	55
72	Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 137-144.	1.1	53

#	ARTICLE	IF	CITATIONS
73	Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. <i>Breast Cancer Research</i> , 2012, 14, R143.	2.2	50
74	Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 319-324.	1.1	49
75	Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": The CASA randomized trial. <i>Breast</i> , 2013, 22, 130-137.	0.9	48
76	Coping with metastatic melanoma: the last year of life. <i>Psycho-Oncology</i> , 2000, 9, 283-292.	1.0	42
77	Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 211-214.	1.1	42
78	Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 211-218.	1.1	41
79	Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. <i>Lancet, The</i> , 1999, 354, 130-131.	6.3	40
80	Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status. <i>Cancer</i> , 2003, 97, 1591-1600.	2.0	40
81	Adjuvant ovarian function suppression and cognitive function in women with breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 956-964.	2.9	38
82	Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12 "93. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 491-500.	1.1	37
83	Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 275-286.	1.1	37
84	Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. <i>Annals of Surgical Oncology</i> , 2017, 24, 398-406.	0.7	29
85	Prognostic Value of Extracapsular Tumor Spread for Locoregional Control in Premenopausal Patients With Node-Positive Breast Cancer Treated With Classical Cyclophosphamide, Methotrexate, and Fluorouracil: Long-Term Observations From International Breast Cancer Study Group Trial VI. <i>Journal of Clinical Oncology</i> , 2005, 23, 7089-7097.	0.8	28
86	Chemotherapy for Advanced Breast Cancer " How Long Should it Continue?. <i>Breast Cancer Research and Treatment</i> , 2003, 81, 49-52.	1.1	27
87	Systemic chemotherapy for malignant melanoma. <i>World Journal of Surgery</i> , 1992, 16, 277-281.	0.8	26
88	CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1 "98 trial. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 373-384.	1.1	26
89	Adjuvant " Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 303-310.	1.1	24
90	A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Locoregional Relapse of Breast Cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. <i>Clinical Breast Cancer</i> , 2008, 8, 287-292.	1.1	23

#	ARTICLE	IF	CITATIONS
91	Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. <i>Breast Cancer Research</i> , 2016, 18, 110.	2.2	22
92	Long-Term Follow-Up of the Intergroup Exemestane Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2507-2514.	0.8	22
93	Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 347-359.	1.1	19
94	Subsets within the chemotherapy overview. <i>Lancet, The</i> , 1998, 352, 1783-1784.	6.3	17
95	Overhauling the breast cancer overview: are subsets subversive?. <i>Lancet Oncology, The</i> , 2002, 3, 525-526.	5.1	16
96	ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 543-555.	1.1	16
97	Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 386-395.	0.8	16
98	Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. <i>SpringerPlus</i> , 2013, 2, 391.	1.2	14
99	Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data. , 1998, 17, 587-601.		13
100	Refining the measurement of psychological adjustment in cancer. <i>Australian Journal of Psychology</i> , 1997, 49, 144-151.	1.4	12
101	Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. <i>Supportive Care in Cancer</i> , 2008, 16, 67-74.	1.0	11
102	The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 295-306.	1.1	11
103	Taxanes as adjuvant for breast cancer. <i>Lancet, The</i> , 2000, 356, 507-508.	6.3	10
104	When do patient reported quality of life indicators become prognostic in breast cancer?. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 13.	1.0	10
105	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. <i>Breast Cancer Research</i> , 2019, 21, 153.	2.2	10
106	Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. <i>Annals of Oncology</i> , 2007, 18, 1177-1184.	0.6	8
107	Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 697-707.	1.1	8
108	Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 879-880.	0.8	7

#	ARTICLE	IF	CITATIONS
109	Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 321-329.	1.1	7
110	Chemotherapy in metastatic melanoma: Phase II studies of amsacrine, mitoxantrone and bisantrene. <i>European Journal of Cancer & Clinical Oncology</i> , 1986, 22, 97-100.	0.9	6
111	Second non-breast primary cancer following adjuvant therapy for early breast cancer: A report from the International Breast Cancer Study Group. <i>European Journal of Cancer</i> , 2009, 45, 561-571.	1.3	6
112	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 351-360.	1.1	5
113	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , 2019, 120, 959-967.	2.9	5
114	Prediction of cancer outcome with microarrays. <i>Lancet, The</i> , 2005, 365, 1685-1686.	6.3	4
115	Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 529-529.	0.8	4
116	Meta AMSA (m-AMSA) in Patients with Advanced Ovarian Carcinoma. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1982, 22, 107-109.	0.4	3
117	Too Early to Say That Pregnancy Has an Antitumor Effect on Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 3707-3708.	0.8	3
118	Chemotherapy of advanced head and neck cancer: Updated results of a randomized trial of the order of administration of sequential methotrexate and 5-fluorouracil. <i>Medical and Pediatric Oncology</i> , 1988, 16, 304-307.	1.0	2
119	Clinical behavior of recurrent hormone receptorâ€“positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1â€™98 clinical trial. <i>Cancer</i> , 2021, 127, 700-708.	2.0	2
120	Desmoplastic and desmoplastic neurotropic melanoma. , 1998, 83, 1128.		2
121	Perioperative Chemotherapy in Patients With Node-Negative Postmenopausal Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 2210-2212.	0.8	0